Pharmaceuticals
I-Mab Announces Share Purchase Plans by the Company and the Senior Management
GAITHERSBURG, Md. and SHANGHAI, Aug. 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it plans to implement share repurchases...
2022-08-23 21:13
4094
Zerion Pharma and Hovione extend partnership to cover use of the Dispersome® technology platform in nutraceuticals
LISBON, Portugal, Aug. 23, 2022 /PRNewswire/ -- Hovione and Zerion Pharma A/S (Zerion) today announced an extension of their collaboration on Zerion's Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in poor...
2022-08-23 17:58
2608
GenScript ProBio Congratulates Selecxine on FDA Clearance of IND Application for Innovative Antibody Drug Program
NANJING, China, Aug. 23, 2022 /PRNewswire/ -- Recently, Selecxine, a partner of GenScript ProBio, announces FDA clearance of its IND application for innovative antibody drug program (SLC-3010). GenScript ProBio was responsible for the CMC development and supporting IND filing in this project. Gen...
2022-08-23 14:15
3666
Announcement of 2022 Future Science Prize Winners: Wenhui Li, Xueming Yang, Ngaiming Mok
BEIJING, Aug. 23, 2022 /PRNewswire/ -- The Future Science Prize committee announces the winners of 2022 onAugust 21st. Prof. Wenhui Li from National Institute of Biological Sciences,Beijing, China; Tsinghua Institute of Multidisciplinary Biomedical Research receives the Future Science Prize in li...
2022-08-23 11:52
3747
Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head
Building a leadership team with global and local experience and expertise to
enable rapid execution across Company's broad therapeutic strategy
DURHAM, N.C. and BEIJING, Aug. 23, 2022 /PRNewswire/ -- Brii Biosciences
2022-08-23 07:30
5068
AVELOS THERAPEUTICS ANNOUNCES $8 MILLON SERIES A FUNDING ROUND
Seoul-Based Biotechnology Company to Use Financing for Expanding Oncology Drug Discovery and Development SEOUL, South Korea, Aug. 22, 2022 /PRNewswire/ -- Innovative biotechnology company specializing in new drug discovery and development, Avelos Therapeutics, has received a glowing endorsement ...
2022-08-22 20:00
2630
LTS takes next step in its Growth Journey with the acquisition of Tapemark Inc.
ANDERNACH, Germany, Aug. 22, 2022 /PRNewswire/ -- LTS LOHMANN Therapie-Systeme AG ("LTS") announces the closing of the acquisition of Tapemark Inc. ("Tapemark") located inSt. Paul, MN, USA. This acquisition combines Tapemark, a world-class CDMO specialized in transdermal drug delivery systems and...
2022-08-22 18:00
2266
The 2022 Smart China Expo kicked off, smart technology empowers Chongqing Liangjiang New Area to lead innovative development
CHONGQING, China, Aug. 22, 2022 /PRNewswire/ -- The 2022 Smart China Expo will be held in Liangjiang New Area of southwest China'sChongqing from August 22 to 24, with the theme of "Smart Technology: Empowering Economy, Enriching Life". As the most influential event in China's intelligent industry...
2022-08-22 15:37
5888
Biosion, Inc. Appoints Steven Knapp, Pharm.D. as Chief Regulatory & Quality Officer
NEWARK, Del. and NANJING, China, Aug. 22, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a leading global R&D biotechnology company, today announced the appointment ofSteven Knapp, PharmD., as Chief Regulatory & Quality Officer. In this position, he is responsible for the strategic leadership...
2022-08-22 13:00
2362
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17
* Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. * Doses of the Novavax COVID-19 Vaccine, Adjuvanted are now available and primary series immunizations for adolescents can beginonce a policy recommendation from the CDC is received GAITHERSBURG, Md., Aug. 2...
2022-08-22 10:05
5388
Sirnaomics Becoming A Constituent of Hang Seng Family of Indexes
HONG KONG, Aug. 22, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or " Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company has been selected as a constituent stock of eight index series including...
2022-08-22 08:33
4162
Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA
-- Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA -- Ascletis has filed multiple patent applications for ASC10 and its use globally. Compared with molnupiravir, ASC10 has a new and differentiated chemical...
2022-08-22 08:10
4023
I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022
- Major updates will focus on global clinical development of core assets, upcoming milestones and financial results - The Company will update on potential implementation of a comprehensive share purchase program by the Company and current shareholders - Conference Calls Scheduled at 7:00 a.m....
2022-08-19 21:00
2926
World's First CAR-T for NMOSD Treatment, IASO Biotherapeutics' Equecabtagene Autoleucel, Receives IND Approval by NMPA
SHANGHAI, NANJING, China and SAN JOSE, Calif., Aug. 19, 2022 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, announced today that the Center for Drug ...
2022-08-19 18:41
2505
Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer
* Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union * Submission supported by results from the pivo...
2022-08-19 18:15
3603
Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ
Data results will be available in Q1 2023 GAITHERSBURG, Md. and SUZHOU, China, Aug. 19, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Compa...
2022-08-19 13:31
3413
Completion Of Subject Enrollment And Vaccination For The Comparative Study Between ReCOV And mRNA Vaccines
TAIZHOU, China, Aug. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Company has completed the subject enrollment and dosing for the comparative Phase II clinical trial between its recombina...
2022-08-19 11:29
3925
Nuance Pharma Announces Clearance of IND Application for Ensifentrine Pivotal Clinical Trials for COPD in China
SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal clinical trial ofEnsifentrine for the maintenance treatment of chronic obstructive pulmonary ...
2022-08-19 11:24
2485
Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ
Data results will be available in Q1 2023 GAITHERSBURG, Md. and SUZHOU, China, Aug. 18, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Compa...
2022-08-18 23:46
2103
Henlius 2022 H1 Results: Sharpen all-round edges, advance in evolution to Biopharma
SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its 2022 interim results. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biopharmaceuticals to patients worldwide with 5 products launched inChina, 1 in ...
2022-08-18 21:35
4406
Week's Top Stories
Most Reposted
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 294 media titles]
2026-10-22 22:35
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 283 media titles]
2026-10-19 13:18
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 278 media titles]
2026-10-23 21:52
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 276 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
30881
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
26337
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
24313
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
24286